Zanubrutinib in Chronic Lymphocytic Leukemia

To the Editor: In the ALPINE trial involving patients with relapsed or refractory chronic lymphocytic leukemia (CLL), Brown and colleagues (Jan. 26 issue) 1 report that the Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib was superior to ibrutinib with respect to the overall response, progressi...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 388; no. 18; pp. 1719 - 1721
Main Authors Byrd, John C., Rothbaum, Wayne, Liang, Yang, Gale, Robert P., Brown, Jennifer R., Cohen, Aileen, Shadman, Mazyar
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 04.05.2023
Subjects
Bruton's tyrosine kinase
Cancer therapies
Chronic lymphocytic leukemia
Conflicts of interest
Coronaviruses
COVID-19
Drug dosages
FDA approval
Humans
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Lymphoma
Lymphoma, B-Cell
Mutation
Patients
Piperidines - therapeutic use
Protein-tyrosine kinase
Stockholders
Survival
United States > US
Online AccessGet full text

Cover

More Information
Summary:To the Editor: In the ALPINE trial involving patients with relapsed or refractory chronic lymphocytic leukemia (CLL), Brown and colleagues (Jan. 26 issue) 1 report that the Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib was superior to ibrutinib with respect to the overall response, progression-free survival, and adverse-events profile. These results mirror those of the ELEVATE-RR trial, 2 which showed a better safety profile with acalabrutinib than with ibrutinib, although the patients had a similar overall response and progression-free survival. Between-trial comparisons of the overall response and progression-free survival are problematic because of baseline and statistical differences. The ELEVATE-RR trial included a higher-risk . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc2302350